EXCALIBER RRMM
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Filters
Save & Share
Clear Filters
Location
Explore options near your patient - or anywhere in the US.
Diagnosis
Treatment History
BCMA Therapy
This stands for B Cell Maturation Antigen (BCMA) and includes treatments such as ide-cel, cilta-cel or belantamab mafodotin.
Near Add Your Location
Sort by
- Accepting patients
- Show Principal Investigator
American Oncology Partners of Maryland (Bethesda)
The Center for Cancer & Blood Disorders - Bethesda
Bethesda, MD
- Accepting patients
- Show Principal Investigator
Dana-Farber Cancer Institute
Boston, MA
- Accepting patients
- Show Principal Investigator
University of Massachusetts Medical School
Worcester, MA
- Accepting patients
- Show Principal Investigator
- Accepting patients
- Show Principal Investigator
- Accepting patients
- Show Principal Investigator
- Accepting patients
- Show Principal Investigator
HCA Midwest Health Research Medical Center
Kansas City, MO
- Accepting patients
- Show Principal Investigator
- Accepting patients
- Show Principal Investigator
Smilow Cancer Hospital at Yale New Haven
New Haven, CT
- Accepting patients
- Show Principal Investigator
115 hidden based on your filters. Show All
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.